Who is sponsoring NCT00634920?

NCT00634920 is sponsored by Novartis Pharmaceuticals.

What condition does NCT00634920 study?

NCT00634920 studies Renal Function.

What drugs are being tested in NCT00634920?

Interventions: everolimus, cyclosporine A, Enteric Coated Mycophenolate Sodium (EC-MPS), corticosteroids, Basiliximab.

What is the status of NCT00634920?

NCT00634920 is currently COMPLETED.

Last reviewed 2014-08-12 · How we verify

A Controlled Randomized Open-label Multicenter Study Evaluating if Early Conversion to Everolimus (Certican) From Cyclosporine (Neoral) in de Novo Renal Transplant Recipients Can Improve Long-term Renal Function and Slow Down the Progression of Chronic Allograft Nephropathy

NCT00634920 Phase 4 COMPLETED Results posted

This study is designed to evaluate if early conversion to everolimus from cyclosporine in de novo renal transplant recipients can improve long-term renal function and slow down the progression of chronic allograft nephropathy

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 4
Status	COMPLETED
Enrolment	204
Start date	2008-03
Completion	2013-05

Conditions

Renal Function

Interventions

everolimus
cyclosporine A
Enteric Coated Mycophenolate Sodium (EC-MPS)
corticosteroids
Basiliximab

Primary outcomes

Measured Glomerular Filtration Rate — Month 12
To compare the efficacy between treatment regimens by assessing the difference in renal function evaluated by mean measured glomerular filtration rate (mGFR) 12 months after renal transplantation (TX). The mGFR was measured using Iohexol or Cr-EDTA clearance according to local practice.

Countries

Denmark, Norway, Sweden